Schaeffer Center for Health Economics and Policy, University of Southern California, Los Angeles, CA, United States of America; School of Pharmacy, University of Southern California, Los Angeles, CA, United States of America.
Division of General Internal Medicine and Geriatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America.
Contemp Clin Trials. 2021 Apr;103:106329. doi: 10.1016/j.cct.2021.106329. Epub 2021 Feb 24.
There is a lack of evidence that long-term opioid use offers benefit for noncancer pain and an abundance of evidence of harm. Despite clinical guidelines and education, prescribing continues at a higher rate than before the opioids crisis. The objective of trial 1 of the Application of Economics & Social psychology to improve Opioid Prescribing Safety (AESOPS-1) is to discourage unnecessary opioid prescribing in primary care by applying "behavioral insights"-empirically-tested social and psychological interventions that affect choice.
AESOPS-1 randomizes primary care clinics in Illinois and California to behavioral intervention or control. Both arms receive opioid guideline education. Clinics randomized to the behavioral intervention arm receive nudges within the electronic health record (EHR) including: 1) an "accountable justification" entered in the chart, 2) a precommitment to address high-risk prescriptions, and 3) a "PainTracker" that broadens discussions about pain. The control arm receives no EHR-based intervention. The primary outcome is the change in weekly milligram morphine equivalents (MME) prescribed. The secondary outcome is the change in the proportion of patients prescribed at least 50 daily MME. To evaluate these outcomes, we will use a difference-in-differences mixed-effects regression model on clinician MME weekly or daily dose. The analysis will be "intent-to-treat." The intervention period is 18-months, with a 6-month follow-up period to measure persistence of effects.
The AESOPS-1 trial will evaluate the effect of EHR-based interventions in reducing noncancer opioid prescribing in primary care. AESOPS-1 may demonstrate practical and scalable strategies to lower unnecessary population exposure to opioids.
长期使用阿片类药物治疗非癌性疼痛是否有益,目前尚无确凿证据,而其危害却有大量证据。尽管有临床指南和教育,但阿片类药物危机之前的开处阿片类药物的比率仍居高不下。应用经济学和社会心理学改善阿片类药物处方安全(AESOPS-1)试验 1 的目的是通过应用“行为洞察力”-经过实证检验的影响选择的社会和心理干预措施,来劝阻初级保健中不必要的阿片类药物处方。
AESOPS-1 将伊利诺伊州和加利福尼亚州的初级保健诊所随机分为行为干预组或对照组。两组均接受阿片类药物指南教育。随机分配到行为干预组的诊所将在电子健康记录(EHR)中收到提示,包括:1)在图表中输入“负责的理由”,2)预先承诺解决高风险处方,以及 3)“疼痛追踪器”,以扩大对疼痛的讨论。对照组不接受基于 EHR 的干预。主要结局是每周开处的吗啡毫克当量(MME)的变化。次要结局是至少开具 50 日常 MME 处方的患者比例的变化。为了评估这些结果,我们将使用基于差异的混合效应回归模型对临床医生每周或每日 MME 进行分析。分析将采用“意向治疗”。干预期为 18 个月,有 6 个月的随访期以测量效果的持久性。
AESOPS-1 试验将评估基于 EHR 的干预措施在减少初级保健中非癌性阿片类药物处方的效果。AESOPS-1 可能展示出实用且可扩展的策略,以降低不必要的人群接触阿片类药物。